CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Barnase-barstar 特异性相互作用调节 CAR-T 细胞对恶性肿瘤的细胞毒性活性
英文原题：Barnase-barstar Specific Interaction Regulates Car-T Cells Cytotoxic Activity toward Malignancy.
查看英文原题
Barnase-barstar Specific Interaction Regulates Car-T Cells Cytotoxic Activity toward Malignancy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 特异性疗法的发展在现代肿瘤学中引发了一场革命。尽管治疗效果显著，但这种新方法由于药代动力学和药效学控制方面的并发症而显示出若干关键局限性。CAR-T 疗法存在的若干严重医学并发症促使了一系列旨在调控其体内活性的尝试。我们提出应用barnase-barstar系统来控制CAR-T 细胞的细胞毒性抗肿瘤活性。为了管理该系统的调控靶向效应，我们提出将经barstar修饰的CAR-T 细胞与基于barnase的分子联合使用。Barnase与特异性针对肿瘤抗原HER2（人表皮生长因子受体2）的designer ankyrin repeat proteins（DARPins）融合。该系统的应用显示出CAR-T 靶向的显著调控效应。
展开英文摘要原文
The development of CAR-T specific therapy made a revolution in modern oncology. Despite the pronounced therapeutic effects, this novel approach displayed several crucial limitations caused by the complications in pharmacokinetics and pharmacodynamics controls. The presence of the several severe medical complications of CAR-T therapy initiated a set of attempts aimed to regulate their activity in vivo.
We propose to apply the barnase-barstar system to control the cytotoxic antitumor activity of CAR-T cells. To menage the regulation targeting effect of the system we propose to use barstar-modified CAR-T cells together with barnase-based molecules. Barnase was fused with designed ankyrin repeat proteins (DARPins) specific to tumor antigens HER2 (human epidermal growth factor receptor 2) The application of the system demonstrates the pronounced regulatory effects of CAR-T targeting.
论文信息
- 作者
- Kalinin RS、Shipunova VO、Rubtsov YP、Ukrainskay VM、Schulga A、Konovalova EV、Volkov DV、Yaroshevich IA
- 单位
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. Roman.Kalinin.93@yandex.ru.Russia
- 期刊
- Doklady. Biochemistry and biophysics2023 Feb
- 原文标识
- PubMed 36653580 · DOI 10.1134/S1607672922700041
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →